Effective long-term prevention of relapse in opioid addiction rests on combining medication-assisted treatment with supportive psychosocial and structural interventions. Evidence from national and international experts shows that medications that stabilize brain chemistry and reduce cravings are the foundation for durable recovery, while behavioral supports and policy changes improve access and retention.
Medications with the strongest evidence
Methadone and buprenorphine have the most consistent evidence for reducing relapse, improving treatment retention, and lowering overdose deaths. Nora Volkow National Institute on Drug Abuse emphasizes that methadone and buprenorphine are lifesaving medications that reduce illicit opioid use and mortality when patients remain in treatment. A systematic review led by Robert Mattick National Drug and Alcohol Research Centre University of New South Wales found that opioid agonist treatments, including methadone and buprenorphine, outperform nonpharmacologic approaches for keeping patients engaged and preventing return to use. Extended-release formulations of naltrexone can also reduce relapse risk for motivated, fully detoxified patients, with clinical trials by Sergey Krupitsky Pavlov State Medical University demonstrating benefits of injectable naltrexone in certain settings, though initiation barriers mean it is not universally applicable.
Psychosocial and structural supports that enhance durability
Medications work best when combined with psychosocial interventions and system-level supports. Contingency management, which provides tangible reinforcement for drug-negative tests, has strong empirical backing; Stephen Higgins University of Vermont has published influential trials showing that contingency management increases abstinence and retention when added to medication. Cognitive-behavioral therapies and motivational approaches help patients develop coping skills and address co-occurring mental health conditions that drive relapse. Structural factors such as clinic availability, regulatory restrictions, transportation, housing stability, and stigma shape outcomes. Rural communities and marginalized populations often face limited access to methadone clinics and buprenorphine prescribers, amplifying relapse risk.
Failure to provide evidence-based medications and supports has clear consequences: higher overdose rates, transmission of infectious diseases, family disruption, and greater social and economic harms to communities. Effective relapse prevention therefore requires integrating medications, behavioral supports, and policy reforms that expand access, reduce stigma, and address social determinants of health.